Rocket Pharmaceuticals, Inc. (RCKT)

Market Cap	1.39B
Revenue (ttm)	n/a
Net Income (ttm)	-199.39M
Shares Out	66.22M
EPS (ttm)	-2.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	942,946
Open	18.08
Previous Close	18.39
Day's Range	17.89 - 20.1
52-Week Range	7.57 - 25.62
Beta	1.27
Analysts	Buy
Price Target	53.67 (+170.0%)
Earnings Date	Nov 2, 2022

About RCKT

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell ...

• Industry: Biotechnology
• CEO: Gaurav Shah
• Employees: 151
• Stock Exchange: NASDAQ
• Ticker Symbol: RCKT

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for RCKT stock is "Buy." The 12-month stock price forecast is 53.67, which is an increase of 169.97% from the latest price.

Price Target

$53.67

(169.97% upside)

Analyst Consensus: Buy

Stock Forecasts